Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina

L. A. Mata-Bourcart, D. D. Waters, A. Bouchard, D. D. Miller, P. Théroux

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Six patients hospitalized with active variant angina were treated for 3 days with the serotonin antagonist ketanserin after a 3 day control period on no medication. The number of variant angina episodes per patient per day was 1.52 ± 1.42 during the control period and 2.05 ± 2.30 during ketanserin therapy (p = NS). Ergonovine was administered in incremental doses of 0.0125 mg to 0.4 mg in the control period, during intravenous ketanserin administration and after 3 days of oral treatment. All 6 patients developed ST elevation during all 3 ergonovine tests. The ergonovine dose at which ST elevation developed was similar in each of the 3 periods. It is concluded that ketanserin is of no value in the treatment of variant angina and that both spontaneous and ergonovine-induced spasm in man are unlikely to be mediated by a serotonergic mechanism.

Original languageEnglish (US)
Pages (from-to)168-171
Number of pages4
JournalCanadian Journal of Cardiology
Volume1
Issue number3
StatePublished - Dec 4 1985

Fingerprint

Ergonovine
Ketanserin
Serotonin
Serotonin Antagonists
Spasm
Intravenous Administration
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina. / Mata-Bourcart, L. A.; Waters, D. D.; Bouchard, A.; Miller, D. D.; Théroux, P.

In: Canadian Journal of Cardiology, Vol. 1, No. 3, 04.12.1985, p. 168-171.

Research output: Contribution to journalArticle

Mata-Bourcart, L. A. ; Waters, D. D. ; Bouchard, A. ; Miller, D. D. ; Théroux, P. / Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina. In: Canadian Journal of Cardiology. 1985 ; Vol. 1, No. 3. pp. 168-171.
@article{5bcae1f3f7ae415ea3c5f87280f53897,
title = "Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina",
abstract = "Six patients hospitalized with active variant angina were treated for 3 days with the serotonin antagonist ketanserin after a 3 day control period on no medication. The number of variant angina episodes per patient per day was 1.52 ± 1.42 during the control period and 2.05 ± 2.30 during ketanserin therapy (p = NS). Ergonovine was administered in incremental doses of 0.0125 mg to 0.4 mg in the control period, during intravenous ketanserin administration and after 3 days of oral treatment. All 6 patients developed ST elevation during all 3 ergonovine tests. The ergonovine dose at which ST elevation developed was similar in each of the 3 periods. It is concluded that ketanserin is of no value in the treatment of variant angina and that both spontaneous and ergonovine-induced spasm in man are unlikely to be mediated by a serotonergic mechanism.",
author = "Mata-Bourcart, {L. A.} and Waters, {D. D.} and A. Bouchard and Miller, {D. D.} and P. Th{\'e}roux",
year = "1985",
month = "12",
day = "4",
language = "English (US)",
volume = "1",
pages = "168--171",
journal = "Canadian Journal of Cardiology",
issn = "0828-282X",
publisher = "Pulsus Group Inc.",
number = "3",

}

TY - JOUR

T1 - Failure of ketanserin, a serotonin inhibitor, to prevent spontaneous or ergonovine-induced attacks of variant angina

AU - Mata-Bourcart, L. A.

AU - Waters, D. D.

AU - Bouchard, A.

AU - Miller, D. D.

AU - Théroux, P.

PY - 1985/12/4

Y1 - 1985/12/4

N2 - Six patients hospitalized with active variant angina were treated for 3 days with the serotonin antagonist ketanserin after a 3 day control period on no medication. The number of variant angina episodes per patient per day was 1.52 ± 1.42 during the control period and 2.05 ± 2.30 during ketanserin therapy (p = NS). Ergonovine was administered in incremental doses of 0.0125 mg to 0.4 mg in the control period, during intravenous ketanserin administration and after 3 days of oral treatment. All 6 patients developed ST elevation during all 3 ergonovine tests. The ergonovine dose at which ST elevation developed was similar in each of the 3 periods. It is concluded that ketanserin is of no value in the treatment of variant angina and that both spontaneous and ergonovine-induced spasm in man are unlikely to be mediated by a serotonergic mechanism.

AB - Six patients hospitalized with active variant angina were treated for 3 days with the serotonin antagonist ketanserin after a 3 day control period on no medication. The number of variant angina episodes per patient per day was 1.52 ± 1.42 during the control period and 2.05 ± 2.30 during ketanserin therapy (p = NS). Ergonovine was administered in incremental doses of 0.0125 mg to 0.4 mg in the control period, during intravenous ketanserin administration and after 3 days of oral treatment. All 6 patients developed ST elevation during all 3 ergonovine tests. The ergonovine dose at which ST elevation developed was similar in each of the 3 periods. It is concluded that ketanserin is of no value in the treatment of variant angina and that both spontaneous and ergonovine-induced spasm in man are unlikely to be mediated by a serotonergic mechanism.

UR - http://www.scopus.com/inward/record.url?scp=0021934777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021934777&partnerID=8YFLogxK

M3 - Article

C2 - 2932205

AN - SCOPUS:0021934777

VL - 1

SP - 168

EP - 171

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

SN - 0828-282X

IS - 3

ER -